Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multimodality therapy for medulloblastoma.

P R Thomas, P K Duffner, M E Cohen

    Cancer
    |February 15, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Economic assessment of aerated constructed treatment wetlands using whole life costing.

    Water science and technology : a journal of the International Association on Water Pollution Research·2019
    Same author

    Erratum.

    Journal of periodontology·2018
    Same author

    Central Nervous System (CNS) Involvement in Acute Nonlymphocytic Leukemia (ANLL).

    Leukemia & lymphoma·2016
    Same author

    Development of health diagnostics based on personalized medical models.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2016
    Same author

    A comprehensive rehabilitation program for chronic patients in a state mental hospital.

    Community mental health journal·2013
    Same author

    Histiocytic sarcoma of the urinary bladder in a dog.

    The Journal of small animal practice·2011
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    Same journal

    Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

    Cancer·2026
    Same journal

    Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

    Cancer·2026
    See all related articles

    Multiagent chemotherapy shows promise for recurrent medulloblastoma, achieving complete responses in most patients. Careful timing of chemotherapy during radiotherapy is crucial to minimize severe toxicity in newly diagnosed cases.

    Area of Science:

    • Pediatric Oncology
    • Neuro-Oncology
    • Chemotherapy Research

    Background:

    • Medulloblastoma is a common malignant brain tumor in children.
    • Recurrent medulloblastoma presents significant treatment challenges.
    • Optimizing chemotherapy regimens is essential for improving patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy and safety of a specific multiagent chemotherapy regimen for recurrent medulloblastoma.
    • To assess the impact of adjuvant chemotherapy combined with radiotherapy in newly diagnosed medulloblastoma.
    • To identify optimal strategies for administering chemotherapy during radiotherapy to mitigate toxicity.

    Main Methods:

    • Treatment of 8 patients with recurrent medulloblastoma using vincristine, BCNU, dexamethasone, and methotrexate (intrathecal and intravenous).

    Related Experiment Videos

  • Five recurrent patients also received low-dose radiotherapy.
  • Treatment of 9 newly diagnosed patients with craniospinal radiation and adjuvant chemotherapy, with modifications in the latter 4 patients.

    • Main Results:

    • All 8 recurrent medulloblastoma patients responded to chemotherapy (6 complete, 2 partial).
    • Median duration of response was 18.8 months; median survival was 32 months.
    • Adjuvant chemotherapy in newly diagnosed patients was highly toxic initially but well-tolerated and effective when intraventricular methotrexate was omitted and chemotherapy delayed until after radiotherapy.

    Conclusions:

    • Multiagent chemotherapy is effective against recurrent medulloblastomas, potentially leading to prolonged remissions.
    • Caution is advised with myelo-suppressive drugs during craniospinal radiotherapy for newly diagnosed medulloblastoma.
    • Intraventricular methotrexate is not recommended; delaying chemotherapy until after radiotherapy improves tolerability and outcomes.